The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000650392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
1/05/2026
Date registered
Help: Date registered
1/06/2026
Date last updated
Help: Date last updated
1/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interactions of NB-9402 in Healthy Adult Volunteers - Part A and B
Scientific title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interactions of NB-9402 in Healthy Adult Volunteers
Additional trial identifiers [1] 317001 0
NB-9402-101
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Diseases of the nervous system 341485 0
Condition category
Condition code
Neurological 337573 337573 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Part A - Single Ascending Dose (SAD).
5 cohorts of 7 participants each will receive either NB-9402 or placebo administered as a single dose oral liquid (via oral syringe) followed by a water rinse and swallow. Dose levels planned are 50mg, 125mg, 250mg, 400mg and 500mg. Each participant will be assigned to receive a single dose of NB-9402 or placebo on Day 1 in a 5:2 randomization ratio (i.e., 5 to NB-9402 and 2 to placebo). Sentinel dosing will occur within each cohort, whereby on Day 1, the first 2 participants will receive NB-9402 or placebo as assigned per a 1:1 randomization ratio. A minimum of 24 hours following sentinel dosing and following safety assessment by the PI, the remaining 5 participants in each cohort will be randomly assigned to receive NB-9402 or placebo in a 4:1 ratio. All participants will be confined in the Clinical Research Unit (CRU) from Days 1 to 4.

Part B - Multiple Ascending Dose (MAD).
3 cohorts of 8 participants each will receive either NB-9402 or placebo daily for 10 days administered as an oral liquid (via oral syringe), followed by a water rinse and swallow. Dose levels planned are 125mg, 250mg and 400mg. Sentinel dosing will occur within each cohort, whereby on Day 1, the first 2 participants will receive NB-9402 or placebo for 10 days in a 1:1 randomization ratio. A minimum of 24 hours following the dose of study drug on Day 3 in these 2 “sentinel” participants and following safety assessment by the PI, the remaining 6 participants in each cohort will be randomly assigned to receive NB-9402 or placebo for 10 days in a 5:1 ratio. Participants in Part B will be confined in the CRU from Days -1 to 13.

Each SAD cohort will occur approximately 3 weeks apart, which will allow time for the Safety Review Committee (SRC) meeting to be conducted after each cohort. MAD1 can start after SAD3 has been completed. Each MAD cohort will occur approximately 4 weeks apart, which will allow time for the SRC meeting to be conducted after each cohort.
Intervention code [1] 333758 0
Treatment: Drugs
Description of the comparator or control
A placebo will be used as a comparator in part A and B. The placebo is an oral solution made up of Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS-LF) with OraSweet and OraPlus.
Control group
Placebo

Outcomes
Primary outcome [1] 345055 0
Evaluate the safety of single ascending oral doses of NB-9402 in healthy volunteers.
Timepoint [1] 345055 0
All AEs will be recorded from the time of signing consent through the end-of-study (EOS) visit. Changes from baseline assessments will be measured at the following timepoints: Clinical lab safety tests Day 1, 2, 4 and 8/EOS. ECGs - Day 1-4 and 8/EOS. Vital signs - Day 1-4 and 8/EOS. Physical Examinations - Day 1-4 and 8/EOS.
Primary outcome [2] 345056 0
Evaluate the safety of multiple ascending oral doses of NB-9402 in healthy volunteers.
Timepoint [2] 345056 0
All AEs will be recorded from the time of signing consent through the end-of-study (EOS) visit. Changes from baseline assessments will be measured at the following timepoints: Clinical lab safety tests Day 1, 3, 7, 10, 13 and 18/EOS. ECGs - Day 1-4, 7-8, 10-11, 13 and 18/EOS. Vital signs - Day 1-4, 7-8, 10-11, 13 and 18/EOS. Physical Examinations - Day 1, 3, 5, 7, 10, 13 and 18/EOS.
Secondary outcome [1] 460327 0
Estimate the pharmacokinetic (PK) profile of NB-9402 after single, ascending oral doses in healthy volunteers.
Timepoint [1] 460327 0
Blood samples will be collected for PK analysis on day 1 at the following timepoints: Predose (within 30 minutes of dose), 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours and 72 hours post-dose.
Secondary outcome [2] 460328 0
Estimate the PK profile of NB-9402 after multiple ascending oral doses in healthy volunteers
Timepoint [2] 460328 0
Blood samples will be collected for PK analysis at the following timepoints: - Day 1: Predose (within 30 minutes of dose), 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours post-dose. - Day 3, 5 and 7: 1 hour and 24 hours post-dose - Day 10: Predose (within 30 minutes of dose), 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours and 72 hours post-dose.

Eligibility
Key inclusion criteria
1. Participant must be >/= 18 years and < /= 65 years old at the time of signing informed consent.
2. Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (ECG) obtained within 28 days before study drug administration. (note: bile acid assay results are not required to confirm eligibility).
3. Baseline laboratory test values within reference ranges based on the blood and urine samples taken at screening and on Day-1 (i.e. before administration of the first dose of study drug). Out of normal ranges values may be accepted by the Investigator, if not clinically significant.
4. Nonsmoker and/or ex-smoker who has discontinued smoking and/or use of nicotine-containing products for at least 3 months prior to the first dose of study drug, confirmed by a negative cotinine test at screening and Day -1. Social smoking is permitted; however, participants must have a negative cotinine test at both screening and on Day -1. Repeat testing may be performed at the Investigator's discretion.
5. Ability to communicate well with the Investigator, in the local language, and to understand and comply with the requirements of the study.
6. Body mass index (BMI) within the range 18 to 32 kg/m2 (inclusive).
7. Females must be either postmenopausal for >/=1 year (or with FSH >/=40 mIU/mL at screening if postmenopausal for < 1 year) or surgically sterile (having undergone bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months. However, to protect against the transfer of the study drug in any bodily fluids, male partners of female participants (whether postmenopausal or surgically sterile) must use a barrier form (e.g., condom) of contraception until the EOS visit or 7 days after the last dose of study drug in case of early termination.
8. Males with female partners of childbearing potential will agree to use barrier contraceptive (i.e., condom) and their female partners must use a highly effective method of contraception from screening to 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period. Males who are abstinent will not be required to use a contraceptive method unless they become sexually active. Males in a same sex relationship must also use a barrier form of contraception against the transfer of the study drug in any bodily fluids until the EOS visit or 7 days after the last dose of study drug in case of early termination.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. History or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
2. Any significant chronic medical illness, as determined by the Investigator.
3. Mentally or legally incapacitated, has significant emotional problems at screening or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years. Note: normal healthy volunteers who have had situational depression without suicidal ideation or behavior may be enrolled in the study at the discretion of the Investigator.
4. The participant has a history of severe drug allergy or hypersensitivity or food allergy, including anaphylaxis.
5. The participant has had surgery or trauma with significant blood loss within the last 3 months prior to the first dose of study drug.
6. The participant has donated more than1 unit (500 mL) of blood within 4 weeks prior to the first dose of study drug.
7. Fever (body temperature >38°C) or symptomatic viral or bacterial infection within 2 weeks prior to screening.
8. Any abnormal vital signs -at screening or before the first administration of study drug- considered to be clinically significant by the Investigator.
9. Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. Fully resected basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with no evidence of recurrence for 1 year are permitted.
10. Breast cancer within the past 10 years.
11. Alanine transaminase (ALT) or aspartate aminotransferase (AST) > 1.5 x upper limit of normal.
12. Bilirubin > 1.5 x upper limit of normal (isolated bilirubin > 1.5 x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin < 35%).
13. Any other clinically significant laboratory abnormality at the screening visit or before the administration of the first dose of study drug.
14. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
15. QTcF interval (QT with Fridericia’s correction) > 450 msec in males and > 470 msec in females (based on the mean of triplicate measurements taken at screening).
16. Females of childbearing potential, irrespective of contraceptive measures taken.
17. Inability to tolerate oral medications.
18. Past or intended use of over-the-counter or prescription medication [including herbal medications] within 14 days before dosing.
19. Live vaccine(s) within 1 month before screening or plans to receive such vaccines during the study.
20. Treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) before dosing.
21. Current participation in any other investigational drug study or receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) before Day -1 for all Parts.
22. Positive prestudy drug or alcohol screen. Retesting will be allowed in the event a false positive outcome is suspected.
23. Positive human immunodeficiency virus (HIV) or hepatitis C antibody test (HCV), or hepatitis B surface antigen (HBsAg) at screening or 3 months before enrollment.
24. Regular alcohol consumption within 6 months before the study defined, current evidence of substance dependence or self-reported alcoholic intake > 2 drinks/day for female participants and > 3 drinks/day for male participants.
25. Use of tobacco products (e.g., cigarettes, e-cigarettes, cigars, smokeless tobacco) confirmed by a positive cotinine test.
26. Regular use of known drugs of abuse or a history of drug abuse within 12 months prior to screening.
27. Sensitivity to any of the study drug, or components thereof, or drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be assigned a unique randomization number in ascending numerical order. The randomization number encodes the participant’s assignment to a treatment (active or placebo) within a cohort, according to the randomization schedule generated before the study by an independent programmer or statistician.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computerized randomization list will be used. Part A: Within each cohort, first 2 participants will be randomized 1:1 (sentinel dosing). Remaining 5 participants will be randomized 4:1 (NB-9402:Placebo) for an overall ratio of 5:2 within each cohort. Part B: Within each cohort, first 2 participants will be randomized 1:1 (sentinel dosing). Remaining 6 participants will be randomized 5:1 (NB-9402:Placebo) for an overall ratio of 6:2 within each cohort.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29407 0
Scientia Clinical Research - Randwick
Recruitment postcode(s) [1] 45728 0
2031 - Randwick

Funding & Sponsors
Funding source category [1] 321599 0
Commercial sector/Industry
Name [1] 321599 0
Nura Bio Inc
Country [1] 321599 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Nura Bio Inc
Address
Country
United States of America
Secondary sponsor category [1] 324407 0
Commercial sector/Industry
Name [1] 324407 0
InClin Pty Ltd
Address [1] 324407 0
Country [1] 324407 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320125 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 320125 0
Ethics committee country [1] 320125 0
Australia
Date submitted for ethics approval [1] 320125 0
01/04/2026
Approval date [1] 320125 0
07/05/2026
Ethics approval number [1] 320125 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149518 0
Dr Christopher Argent
Address 149518 0
Scientia Clinical Research, The Bright Building, Level 5, Corner High & Avoca Streets, Randwick NSW 2031
Country 149518 0
Australia
Phone 149518 0
+61 2 9382 5800
Fax 149518 0
Email 149518 0
Contact person for public queries
Name 149519 0
Mr Taylor Kilfoil
Address 149519 0
InClin Pty Ltd, Suite 210, 25/29 Berry Street, North Sydney, NSW, Australia, 2060.
Country 149519 0
Australia
Phone 149519 0
+61 408 880 403
Fax 149519 0
Email 149519 0
Contact person for scientific queries
Name 149520 0
Mr Taylor Kilfoil
Address 149520 0
InClin Pty Ltd, Suite 210, 25/29 Berry Street, North Sydney, NSW, Australia, 2060.
Country 149520 0
Australia
Phone 149520 0
+61 408 880 403
Fax 149520 0
Email 149520 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.